Abstract: Objective To explore the expression trend and clinical value of ANAPC5 as well as the potential molecular mechanism of ANAPC5 involving in the progression of HCC. Methods Combined with HCC gene microarrays and RNA-seq data worldwide, Wilcoxon test was used to analyze the comprehensive expression of ANAPC5 in HCC by combining SMD. Simultaneously, its clinical value and related pathway analysis in HCC was evaluated. Results By analyzing the results of gene microarray or RNA-seq data of 3820 HCC samples and 3091 non-HCC samples, the combined SMD=0.71（95%CI： 0.55~0.88）, with obvious heterogeneity. The AUC=0.81, sensitivity=0.69 （95%CI： 0.60~0.77）, specificity= 0.81（95%CI： 0.73~0.88）, positive likelihood ratio= 3.78 （95%CI： 2.63~5.47）, negative likelihood ratio=0.39 （95%CI： 0.29~0.48）. Enrichment analysis showed that ANAPC5 was related to ribosome, spliceosome, cell cycle pathways. Conclusion Up_regulation of ANAPC5 may play a role in promoting HCC development.

Key words: hepatocellular carcinoma, ANAPC5, clinical value, pathway analysis

摘要： 目的 探讨ANAPC5表达趋势及临床价值以及该分子在肝细胞癌（HCC）进展中参与的潜在生物学机制。方法 联合来自世界范围内的HCC基因芯片及mRNA测序数据,使用Wilcoxon检验,通过合并标准化平均差（SMD）分析ANAPC5在肝细胞癌组织中的综合表达状况,评估其在肝细胞肝癌组中的临床价值及潜在参与的相关生物学通路。结果 通过分析3820个HCC样本和3091个正常样本的高通量数据的结果,SMD=0.71（95%CI：0.55~0.88）。SROC曲线下面积为0.81,根据诊断试验结果,敏感度为0.69（95%CI：0.60~0.77）,特异度为0.81（95%CI：0.73~0.88）,阳性似然比为3.78（95%CI：2.63~5.47）,阴性似然比为0.39（95%CI：0.29~0.48）。富集分析结果显示,ANAPC5与核糖体、剪接体、细胞周期等通路相关。结论 ANAPC5上调在HCC中可能发挥促癌作用。

关键词: 肝细胞肝癌, ANAPC5, 临床价值, 通路分析